AVEO Pharmaceuticals (AVEO) Earns Daily Media Impact Score of 0.15
Press coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.4627078521721 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Lookout for Price Target? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Eldorado Gold Corporation (NYSE:EGO … – Market Breaking Point (press release) (journalfinance.net)
- Buying Penny Stocks in 2017 Just Got Easier with This 1 Tip (moneymorning.com)
- Volume Moving the Tape For Aveo Pharmaceuticals Inc (AVEO) – Stock Press Daily (stockpressdaily.com)
- AVEO Pharmaceuticals (AVEO) Receives Daily News Sentiment Score of 0.18 – ExpressNewsline (expressnewsline.com)
- AVEO Pharmaceuticals Sees Unusually Large Options Volume (AVEO) (americanbankingnews.com)
AVEO has been the subject of a number of recent research reports. FBR & Co reissued an “outperform” rating and set a $3.00 price objective on shares of AVEO Pharmaceuticals in a research report on Monday, May 22nd. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. ValuEngine downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies reissued a “positive” rating on shares of AVEO Pharmaceuticals in a research report on Friday, June 23rd. Finally, BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $3.08.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) traded up 1.32% during midday trading on Friday, hitting $3.07. 2,633,582 shares of the stock were exchanged. The stock’s market cap is $363.20 million. The firm’s 50-day moving average is $2.66 and its 200-day moving average is $1.24. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.30.
COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/19/aveo-pharmaceuticals-aveo-earns-daily-media-impact-score-of-0-15.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.